Paired DNA and RNA sequencing from 840,000 consecutive individuals: Impact on yield in inherited gastrointestinal cancer genes and therapeutic options

CGA-IGC 2026

Nov 02, 2026
Oncology
Presentation

Magan Trottier, Carolyn Horton, Lily Hoang, Jessica Grzybowski, Heather Zimmermann, Jesus Ramirez Castano, Sami Belhadj, Marcy Richardson, Rachid Karam

Background and Aim
RNA sequencing has been shown to improve detection and interpretation of DNA variants. Here, we report outcomes of paired DNA and RNA sequencing in greater than 840,000 individuals who underwent hereditary cancer multi-gene panel testing at a single diagnostic laboratory.

 

Methods
We retrospectively reviewed concurrent DNA/RNA sequencing results from 3/2019 to 8/2025. Variants in autosomal recessive genes and lower-risk (likely) pathogenic variants (PVs; e.g., APC p.I1307K) were excluded. Positive yield and resolution of variants of uncertain significance (VUS) were calculated by comparing variant classifications before and after application of RNA evidence for inherited gastrointestinal cancer (IGC) genes; genes considered to have surgical or therapeutic implications are underlined: APC, ATM, AXIN2, BMPR1A, BRCA1, BRCA2, CDH1, CDKN2A, CTNNA1, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RNF43, RPS20, SMAD4, STK11, TP53.

 

Results
Among 841,976 cases, the positive rate was 9.1% (78,763 PVs in 76,201 individuals) and the rate of uncertainty was 21.3% (205,519 VUS in 179,013 individuals). For 1,659 IGC gene variants, RNA evidence led to medically significant upgrades or novel detection, increasing positive yield by 3.2%; 20.3% of these variants were unique and 97.4% were in genes with surgical/therapeutic implications. RNA upgrades were most common in BMPR1A, ATM, PTEN, CDH1, and APC (>5% increased yield each). RNA evidence also reduced VUS results by 8.3%, with 77.6% of resolved variants downgraded. RNA analysis had greater impact in non-White than non-Hispanic White individuals (proportion of RNA-dependent reclassifications was 72.3% vs 61.2%, p<0.001 and VUS resolutions was 36.2% vs 21.5%, p<0.001).

 

Conclusions
RNA evidence led to a 3.2% relative increased yield of PVs and 8.3% relative decrease in VUS results in IGC genes, which is higher than prior reports and suggests improved utility over time. Most of the increased positive yield occurred in genes with treatment implications. RNA paired with DNA sequencing also improved equity in genetic testing.